electronic medical records

Geisinger and Eisai to test real-world validity of AI-powered Passive Digital Marker (PDM) in detecting early cognitive impairment and dementia

by

Research col­lab­o­ra­tion will test nov­el algorithm’s effec­tive­ness on Geisinger data (press release):

Geisinger and Eisai Inc. today announced a col­lab­o­ra­tive effort to study the poten­tial effec­tive­ness of an arti­fi­cial intel­li­gence (AI) tool in the detec­tion of cog­ni­tive impair­ment that could iden­ti­fy demen­tias, includ­ing Alzheimer’s dis­ease (AD). If effec­tive, the AI tool could poten­tial­ly be devel­oped to sup­port the ear­ly detec­tion and stag­ing of cog­ni­tive impair­ment and demen­tia, lead­ing to appro­pri­ate addi­tion­al test­ing for the clin­i­cal, bio­log­i­cal diag­no­sis and treat­ment of demen­tias such as AD. [Read more…] about Geisinger and Eisai to test real-world valid­i­ty of AI-pow­ered Pas­sive Dig­i­tal Mark­er (PDM) in detect­ing ear­ly cog­ni­tive impair­ment and dementia

First, do no harm? Study finds association between androgen deprivation therapy and increased risk of Alzheimer’s disease

by

prostate_cancer_therapyPros­trate Can­cer Treat­ment Tied To Alzheimer’s Risk (New York Times):

“Hor­mone ther­a­py, a com­mon treat­ment for prostate can­cer, is asso­ci­at­ed with an increased risk for Alzheimer’s dis­ease, a new study has found…Overall, those treat­ed with hor­mone ther­a­py had an 88 per­cent increased risk of Alzheimer’s com­pared with oth­er patients. The longer [Read more…] about First, do no harm? Study finds asso­ci­a­tion between andro­gen depri­va­tion ther­a­py and increased risk of Alzheimer’s disease